Back to today’s briefing

Story perspectives

Galleri Blood Test Fails to Reduce Late-Stage Cancers

2/23/2026

28 6 Full Breakdown

Summary

Story summary

A UK study of the Galleri blood test with 142,000 participants failed to achieve a 20% reduction in late-stage cancers.
Experts expressed skepticism about claims of earlier-stage detections.
Grail, the company behind Galleri, saw its stock fall 50% after the announcement as it plans to extend the trial and pursue FDA approval, with nearly 500,000 tests sold since 2021.
Galleri costs $949 and is not covered by Medicare.

1 of 1

Story summary

A UK study of the Galleri blood test with 142,000 participants failed to achieve a 20% reduction in late-stage cancers.
Experts expressed skepticism about claims of earlier-stage detections.
Grail, the company behind Galleri, saw its stock fall 50% after the announcement as it plans to extend the trial and pursue FDA approval, with nearly 500,000 tests sold since 2021.
Galleri costs $949 and is not covered by Medicare.